## THE LIVER MEETING® 2019 AT-A-GLANCE

*Indicates that an additional fee is required for this session.*

<table>
<thead>
<tr>
<th>FRIDAY</th>
<th>November 8 (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am-</td>
<td>Liver Fibrosis SIG</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Novel Approaches to Study and Treat Liver Fibrosis: From Bedside to Bench and Bed Again? p. 14</td>
</tr>
<tr>
<td>10:30 am-</td>
<td>Public Health/Healthcare Delivery SIG</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Population Screening for Liver Disease Worldwide p. 15</td>
</tr>
<tr>
<td>1-4 pm</td>
<td>AASLD/NASPGHAN Pediatric Symposium</td>
</tr>
<tr>
<td>2-4 pm</td>
<td>Acute Liver Failure p. 15</td>
</tr>
<tr>
<td>2-4 pm</td>
<td>Career Development Workshop p. 15</td>
</tr>
<tr>
<td>2-4 pm</td>
<td>Clinical Practice SIG</td>
</tr>
<tr>
<td>2-4 pm</td>
<td>Controversies in Clinical Hepatology p. 15</td>
</tr>
<tr>
<td>2-4 pm</td>
<td>Hepatitis B SIG</td>
</tr>
<tr>
<td>2-4 pm</td>
<td>Updates and Controversies in HBV: Management, HCC Surveillance and Emerging Therapies p. 16</td>
</tr>
<tr>
<td>2-4 pm</td>
<td>Liver Cell Biology in Hepatic Diseases SIG</td>
</tr>
<tr>
<td>4:30-6:30 pm</td>
<td>Academic Debates p. 16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SATURDAY</th>
<th>November 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am-7:30 pm</td>
<td>Registration p. 31</td>
</tr>
<tr>
<td>6:45-7:45 am</td>
<td>Early Morning Workshops p. 28</td>
</tr>
<tr>
<td>8 am-5 pm</td>
<td>Basic Science Symposium</td>
</tr>
<tr>
<td>5 pm</td>
<td>Current Trends in Liver Regeneration and Repair p. 11</td>
</tr>
<tr>
<td>8 am-5 pm</td>
<td>Postgraduate Course</td>
</tr>
<tr>
<td>5 pm</td>
<td>Precision Hepatology in Clinical Practice p. 9</td>
</tr>
<tr>
<td>11:45 am-1:30 pm</td>
<td>Meet-the-Professor Luncheons</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Clinical ( Noon-1:30 pm)</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Basic (11:45 am-1:15 pm)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 1-5 pm     | Transplant Surgery Workshop  
Liver Transplantation for NASH: Optimizing Outcomes p. 16 |
| 2-7 pm     | Poster Session II  
(Presentation Time: 5:15-6:15 pm) p. 23 |
| 5-7:30 pm  | Exhibits Open                                                        |
| 5-7:30 pm  | Opening Reception                                                    |
| **SUNDAY** | November 10                                                          |
| 6:30 am-6 pm | Registration Hours p. 31                                             |
| 6:45-7:45 am | Early Morning Workshops p. 29                                       |
| 7-8 am     | Academic Skills Workshop  
Grant Writing p. 17                                                     |
| 8-9:30 am  | Liver Transplant Plenary I p. 23                                     |
| 8 am-Noon  | Basic Research Workshop  
A New Era of Genomics and Biomarkers in Hepatocellular Carcinoma p. 17 |
| 8 am-Noon  | Hepatology Associates Course p. 17                                   |
| 8 am-5:30 pm | Poster Session III  
(Presentation Time: 12:30-1:30 pm) p. 23 |
| 8:30-10 am | Parallel Sessions p. 24                                             |
| 9:30-10 am | Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture  
Clinical vs. Science in Personalizing Immunosuppression p. 17 |
| 9:30 am-3 pm | Exhibits Open                                                        |
| 10:30 am-Noon | General Hepatology Update p. 18                                      |
| 10:30 am-Noon | Liver Transplant Plenary II p. 23                                    |
| 10:30 am-Noon | Parallel Sessions p. 24                                             |
| 10:30 am-12:30 pm | Alcoholic Liver Disease SIG  
Emerging Therapies and Current Clinical Trials for Alcoholic Hepatitis p. 18 |
| 10:30 am-12:30 pm | Diversity Workshop  
Social Innovation: Solution-Based Responses to Disparities in Liver Diseases and Liver Transplantation p. 18 |

**MONDAY** November 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am-6 pm</td>
<td>Registration Hours p. 31</td>
</tr>
<tr>
<td>6:45-7:45 am</td>
<td>Early Morning Workshops p. 30</td>
</tr>
</tbody>
</table>
| 7-8 am     | Academic Skills Workshop  
Journal Editors Session: How to Get Published in an AASLD Journal 2.0 p. 20 |
| 9:30 am-3 pm | Exhibits Open                                                        |
| 10:30 am-Noon | Parallel Sessions p. 24                                             |
| 10:30 am-12:30 pm | Distinguished Award Presentations  
(Distinguished Service, Achievement and Clinician Educator/Mentor Awards) |
<p>| 9:30 am-3 pm | Exhibits Open                                                        |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-10:30 am</td>
<td>Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture</td>
</tr>
<tr>
<td></td>
<td>Genetic Susceptibility to Drug-Induced Liver Injury p. 20</td>
</tr>
<tr>
<td>10:30 am-Noon</td>
<td>Parallel Sessions p. 24</td>
</tr>
<tr>
<td>10:30 am-12:30 pm</td>
<td>Advances for Practitioners</td>
</tr>
<tr>
<td></td>
<td>New AASLD Guidelines: Updated Recommendations and Ongoing Challenges in HCC, PBC and ALD p. 20</td>
</tr>
<tr>
<td>11 am-12:30 pm</td>
<td>Presidential Plenary (Basic) p. 23</td>
</tr>
<tr>
<td>2-2:30 pm</td>
<td>Hans Popper Basic Science State-of-the-Art Lecture</td>
</tr>
<tr>
<td></td>
<td>Distributed Hepatocytes in Liver Homeostasis and Regeneration p. 21</td>
</tr>
<tr>
<td>2:3:30 pm</td>
<td>Parallel Sessions p. 24</td>
</tr>
<tr>
<td>2-4 pm</td>
<td>Emerging Trends Symposium</td>
</tr>
<tr>
<td></td>
<td>Microelimination of Viral Hepatitis–Positive Use in Organ Transplantation p. 21</td>
</tr>
<tr>
<td>2-4 pm</td>
<td>Global Forum</td>
</tr>
<tr>
<td></td>
<td>Alcohol-Related Liver Disease: Seeking Local Solutions to a Global Problem p. 21</td>
</tr>
<tr>
<td>2-6 pm</td>
<td>Liver Transplantation and Surgery SIG and Pediatric Liver Disorders SIG</td>
</tr>
<tr>
<td></td>
<td>Optimizing Allograft Health Over a Lifetime p. 21</td>
</tr>
<tr>
<td>2:30-4 pm</td>
<td>Late-Breaking Oral Abstract Session I</td>
</tr>
<tr>
<td>4-4:30 pm</td>
<td>Basic Debrief</td>
</tr>
<tr>
<td></td>
<td>p. 22</td>
</tr>
<tr>
<td>4-6 pm</td>
<td>Women’s Health Program</td>
</tr>
<tr>
<td></td>
<td>Pregnancy in Liver Disease p. 22</td>
</tr>
<tr>
<td>4:30-6 pm</td>
<td>Parallel Sessions p. 24</td>
</tr>
</tbody>
</table>

**TUESDAY November 12**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am-1:30 pm</td>
<td>Registration p. 31</td>
</tr>
<tr>
<td>8-9 am</td>
<td>Late-Breaking Oral Abstract Session II p. 24</td>
</tr>
<tr>
<td>9-10:30 am</td>
<td>Presidential Plenary (Translational) p. 23</td>
</tr>
<tr>
<td>10:30 am-11 am</td>
<td>Leon Schiff State-of-the-Art Lecture</td>
</tr>
<tr>
<td></td>
<td>Molecular Pathogenesis and Management of Hepatocellular Carcinoma p. 22</td>
</tr>
<tr>
<td>11:30 am-Noon</td>
<td>Hepatitis Debrief p. 22</td>
</tr>
<tr>
<td>Noon-12:30 pm</td>
<td>NAFLD Debrief p. 22</td>
</tr>
<tr>
<td>12:30-1 pm</td>
<td>Clinical Hepatology Debrief p. 22</td>
</tr>
</tbody>
</table>

3 The Liver Meeting® 2019
Precision Hepatology in Clinical Practice

SATURDAY
November 9
8 am-5 pm

7.0 CME Credits
7.0 ABIM MOC Points
7.0 ABP MOC Points
6.5 CE Credits

*Eligible for 3.5 pharmacology hours

Hepatology practice is undergoing major changes fueled by the discovery of disease biomarkers and digital strategies to stage and monitor clinical courses. Once glimpses of a possible future, minimally invasive tests and electronic resources are increasingly available in the clinic. In this Postgraduate Course, experts review how these advances improve care protocols and allow for precise, even customized clinical approaches.

PROGRAM CHAIRS

Jorge A. Bezerra, MD, FAASLD
Andrew P. Keaveny, MD, FRCPI, FAASLD
Rebecca G. Wells, MD
# Postgraduate Course
## Program Agenda

### SESSION I: Precision Medicine in 2019
- **Moderators:** Meena B. Bansal and Ronald J. Sokol
- The Spectrum of Precision Medicine | Konstantinos N. Lazaridis
- Influence of the Microbiome on Liver Disease Phenotype and Outcome | Bernd Schnabl
- Precision Medicine and Patients at Risk for Drug-Induced Liver Injury* | Robert J. Fontana
- Clinical Models and Risk Assessment: Acute on Chronic Liver Failure as a Paradigm | Jennifer C. Lai

### SESSION II: Evolution of Disease and Reversing Fibrosis
- **Moderators:** Rohit Loomba and Rebecca G. Wells
- Nonalcoholic Fatty Liver Disease: Non-Invasive Phenotyping | Mary E. Rinella
- Phenotyping NAFLD: Risk Stratification and Managing Co-Morbidities* | Kymberly Watt
- Reversing Liver Fibrosis: Predicting and Monitoring Structural Changes* | Don C. Rockey

### SESSION III: Autoimmune Diseases and Cholestasis
- **Moderators:** Ulrich Beuers and Vicky L. Ng
- Precision Therapy in Patients with Primary Biliary Cholangitis* | Michael H. Trauner
- Predictors of Disease Progression and Complications of Primary Sclerosing Cholangitis | Tom H. Karlsten
- Autoimmune Liver Disease in Younger Patient: Crossing Phenotypic Boundaries* | Alexander G. Miethke
- Biliary Atresia: Biomarkers of Disease and Predictors of Outcome* | Cara L. Mack
- Meet-the-Professor Luncheons (Ticketed Activity)$!

### SESSION IV: Hepatic Neoplasms
- **Moderators:** Lopa Mishra and Andrew P. Keaveny
- Managing HCV Cirrhotic Patients After Achieving SVR: Who Will Progress to Developing Hepatocellular Carcinoma?* | Tushar Patel
- Non-Invasive Assessment of Small Liver Lesions | Kathryn Fowler Precision
- Medicine to Guide Therapy in Liver Cancer | Josep M. Llovet Emerging
- Treatment Options for HCC and Cholangiocarcinoma* | Laura M. Kulik

### SESSION V: Questions, Controversies and Value of Care
- **Moderators:** Nancy Reau and Raymond T. Chung
- Genetic Testing in Adults with Liver Disease: Improving Diagnostic Algorithms | Verena Keitel
- Precision Treatment of HBV: Envisioning Curative Therapies* | Norah Terrault
- Personalizing Longitudinal Care of Patients with Cirrhosis | Fasiha Kanwal
- Case-Based Debate: Balancing the Costs and Benefits of Individualized Medicine*
  - Moderator: Scott L. Friedman | Discussants: Michael R. Lucey and Gyongyi Szabo
- From Discovery Science to Clinical Care: Where Do We Want to Go? | Scott L. Friedman
The liver is constantly exposed to external and internal damaging factors, yet it can regenerate and repair itself. With the help of novel tools, we now know more about the mechanisms of this process. At this symposium, experts report new research on liver regeneration and repair and how this knowledge may facilitate clinical applications to rescue and restore liver function.
# Basic Science Symposium
## Program Agenda

### SESSION I: Liver Regeneration  
**Moderators:** Xiao-Ming Yin and Bilon Khambu

- **Receptor Tyrosine Kinase Pathways in Normal and Regenerating Liver** | George K. Michalopoulos
- **Hepatic Macrophages in Liver Regeneration** | Frank Tacke
- **Stellate Cells in Normal and Regenerative Liver Biology** | Robert F. Schwabe
- **Developmental Pathways in Liver Regeneration** | Satdarshan (Paul) Singh Monga

### SESSION II: Hepatocyte-Biliary Cell Transdifferentiation  
**Moderators:** George K. Michalopoulos and Tiangang Li

- **Cholangiocyte Proliferation in Liver Regeneration** | Gianfranco Alpini
- **Cholangiocyte Development and Repair** | Stacey S. Huppert
- **Liver Regeneration and Facultative Stem Cell Functions in Cholangiocytes** | Kari Nejak-Bowen

### SESSION III: Hepatic Progenitor Cells and Liver Repair  
**Moderators:** Robert F. Schwabe and Liya Pi

- **Role of Hepatic Progenitor Cells in Liver Injury** | Markus Grompe
- **Senescence, Ductular Reaction and Hepatic Progenitor Expansion** | Stuart J. Forbes
- **Autophagy Regulates the Expansion of Hepatic Progenitor Cells in Liver Injury** | Xiao-Ming Yin
- **Hepatic Progenitor Cells in Liver Regeneration and Reprogramming** | Atsushi Miyajima

### SESSION IV: Hepatic Reconstitution with iPSC and Liver Stem Cell Culture  
**Moderators:** Satdarshan (Paul) Singh Monga and Wen-Xing Ding

- **Stem Cells, Organoid Culture for Liver Regeneration** | Hideki Taniguchi
- **Methodologies and Applications Related to iPSC Hepatocytes in Normal and Decellularized Livers** | Alejandro Soto-Gutierrez
- **iPSC Hepatocytes: Successes and Hopes for Therapies** | Stephen A. Duncan
ANNUAL MEETING

Annual Meeting programming includes Special Interest Group (SIG) programming, abstract-based sessions (plenaries, parallel sessions and posters) and a variety of other lectures, workshops and symposia. Annual Meeting programming is included in all registration packages (Flex, Clinical and Basic), or you can register for Annual Meeting only. See registration options on p. 31.

Friday, November 8

Cholestatic and Autoimmune Liver Diseases SIG

Bile Acid Signaling and Cholestatic Liver Diseases

FRIDAY, NOVEMBER 8 | 8-10 am
Program Chairs: Carlo Spirli and Cynthia Levy

Recent approval of the synthetic FXR agonist obeticholic acid for primary biliary cholangitis treatment shows that targeting nuclear receptors in treating liver diseases, particularly cholestatic and autoimmune conditions, has therapeutic potential. At this symposium, translational researchers and clinical investigators with expertise in cholestatic diseases will review recent pre-clinical and clinical studies and discuss rapidly emerging novel and efficient therapies.

Hepatotoxicity SIG

Drug-Induced Liver Injury: Assessing Risk and Predicting Outcome

FRIDAY, NOVEMBER 8 | 8-10 am
Program Chairs: Victor J. Navarro and Adrian Reuben

Clinicians and translational researchers will glean approaches to assess drug-induced liver injury (DILI) risk and predict outcomes at this session. Faculty will review basic hepatic drug metabolism in healthy and diseased livers, strategies to detect DILI during drug treatment and possible DILI risk factors, such as dose, duration, genetics and immunity. They will also share useful databases for clinicians.

Nonalcoholic Fatty Liver Disease SIG

NAFLD Progression: A Cross Talk with Microbiome

FRIDAY, NOVEMBER 8 | 8-10 am
Program Chairs: Mazen Noureddin and Kathleen E. Corey

At this symposium, experts share the latest advances in the research of the microbiome and its relationship with NAFLD. They will discuss the microbiome’s association with disease progression, fibrosis and hepatocellular carcinoma. Topics covered will include the “cross talk” between obesity, the microbiome and NAFLD in both animal models and humans.
Acute on Chronic Liver Failure SIG and Portal Hypertension SIG
Acute and Chronic Kidney Failure in Cirrhosis: Mechanisms to Management
FRIDAY, NOVEMBER 8 | 8-Noon
Program Chairs: Elizabeth C. Verna and Puneeta Tandon
3.75 CME Credits
This two-session program explores the pathophysiology, diagnosis and treatment of kidney failure in patients with cirrhosis. The first session reviews chronic kidney manifestations of portal hypertension, including sodium retention, ascites and chronic kidney failure. The second session discusses acute kidney injury in ACLF. Each part includes a case presentation to highlight management controversies, expert panel interviews and Q&A.

Clinical Research Workshop
Microbiome as a Model of Clinical Research: From Stool to Study to Treatment
FRIDAY, NOVEMBER 8 | 9-Noon
Program Chairs: Mamatha Bhat and Kenneth D. Chavin
2.0 CME Credits
The microbiome is recognized as an important player in liver disease pathogenesis. The liver’s close proximity to the gut makes it particularly susceptible to changes in the intestinal microbiome. This workshop uses the microbiome as an example to facilitate appreciation of the tools available to perform clinical research, as well as specific research tactics for micro-biome-related study.

Hepatitis C SIG
Improving the Care Continuum for Chronic HCV Infection in 2019
FRIDAY, NOVEMBER 8 | 10:30 am-12:30 pm
Program Chairs: Andrew J. Muir and Nancy Reau
2.0 CME Credits
2.0 ABIM MOC Points
Review steps to develop programs to eradicate HCV in the U.S. at this program. Speakers will address the current state of screening, novel models to engage more patients into therapy and the current state of access to HCV therapeutics, including generics. They will contrast U.S. efforts to eradicate HCV with programs from around the world.

Liver Fibrosis SIG
Novel Approaches to Study and Treat Liver Fibrosis: From Bedside to Bench and Bed Again?
FRIDAY, NOVEMBER 8 | 10:30 am-12:30 pm
Program Chairs: Meena B. Bansal and Ekihiro Seki
2.0 CME Credits
Experts review recent progress in liver fibrosis research at this session, focusing on new discoveries of the molecular mechanisms and translational aspects of fibrosis and cirrhosis, including translation of findings into humans; the potential role of non-parenchymal cells; new transcriptional and post-transcriptional regulation of key contributors of fibrosis; mechanisms that may lead to novel therapies; and an update on antifibrotics.
Public Health/ Health Care Delivery SIG

Population Screening for Liver Disease Worldwide
FRIDAY, NOVEMBER 8 | 10:30 am-12:30 pm
Program Chairs: Sumeet K. Asrani and Steven J. Scaglione
2.0 CME Credits

This timely program tackles the eternal question of how to best screen for liver disease in the general population. Speakers will take a global perspective to describe novel methods of screening, discuss high-risk patient populations and address issues of cost effectiveness and linkage to care.

AASLD/NASPGHAN Pediatric Symposium

Acute Liver Failure
FRIDAY, NOVEMBER 8 | 1-4 pm
Program Chairs: James E. Squires and Estella M. Alonso
2.75 CME Credits

At this symposium, experts on pediatric acute liver failure (PALF) will review the role of inflammation in etiopathogenesis of common comorbidities and discuss emerging topics in pediatric acute on chronic liver failure and extrahepatic support strategies. They will discuss the complexity of medical decision making in PALF and review indications for liver transplant in these patients.

Career Development Workshop

FRIDAY, NOVEMBER 8 | 2-4 pm
Program Chairs: Michelle T. Long and Aparna Goel
No CME Offered

The Career Development Workshop is designed for hepatologists in the early career stage. Participants will explore how to maximize career opportunities in basic and clinical research, and will discuss potential sources of research funding for each pathway. They will also review an array of career pathways in both academic and community practice, and possible rewards and challenges hepatologists may encounter.

Clinical Practice SIG

Controversies in Clinical Hepatology
FRIDAY, NOVEMBER 8 | 2-4 pm
Program Chairs: Paul J. Thuluvath and Kris V. Kowdley
2.0 CME Credits 2.0 ABIM MOC Points

What are the hotly debated issues in clinical hepatology today? At this session, explore current controversies in the field, including the role of statins, optimal management of acute gastric variceal bleeding and treatment of HCV in people who inject drugs. Speakers will then propose evidence-based guidance to address these difficult or challenging issues.
**Hepatitis B SIG**  
*Updates and Controversies in HBV: Management, HCC Surveillance and Emerging Therapies*  

FRIDAY, NOVEMBER 8 | 2-4 pm  
Program Chairs: Mindie H. Nguyen and James S. Park  
2.0 CME Credits  

This two-hour symposium explores chronic hepatitis B management in diverse populations. Topics include the changing global epidemiology and comorbidity of chronic hepatitis B, how to apply current practice guidelines in “gray” zones, HCC prevention strategies beyond the guidelines, emerging curative therapies and current strategies in HCC surveillance for hepatitis B, especially in younger, noncirrhotic persons from endemic areas.

**Liver Cell Biology in Hepatic Diseases SIG**  
*Regenerative Medicine and the Bio-Artificial Liver*  

FRIDAY, NOVEMBER 8 | 2-4 pm  
Program Chairs: Steven A. Weinman and Bryon E. Petersen  
2.0 CME Credits  

Recent advances in liver bio-engineering have led to multiple in vitro culture systems that duplicate many complex cell-cell interactions of the intact liver. This symposium will highlight recent advances in this field, show current use of ex-vivo, 3D multicellular culture systems as probes of liver function and disease and update the progress toward the generation of the bio-artificial liver.

**Academic Debates**  
*FRIDAY, NOVEMBER 8 | 4:30-6:30 pm*  
Program Chairs: Ian R. Schreibman, Christina C. Lindenmeyer and Oren K. Fix  
2.0 CME Credits 2.0 ABIM MOC Points  

Explore timely topics in liver disease in a lively debate format as transplant hepatology trainees and practicing hepatologists tackle important, often controversial issues. Debaters will gain skills in critical thinking, balanced argumentation and factual examination of each issue’s pros and cons. Debaters, judges and audience members will grapple with opposing scientific, societal, individual and financial viewpoints on current clinical concerns.

**Saturday, November 9**  

**Transplant Surgery Workshop**  
*Liver Transplantation for NASH: Optimizing Outcomes*  

SATURDAY, NOVEMBER 9 | 1-5 pm  
Program Chairs: Bijan Eghtesad and John F. Renz  
3.75 CME Credits  

Nonalcoholic steatohepatitis has become a leading indication for liver transplantation in the United States and worldwide. At this symposium, faculty will review pre-transplant evaluation and assessment of comorbid conditions in these patients, early and long-term challenges after transplantation, patterns of recurrence of the disease and potentially preventive strategies.
**Sunday, November 10**

**Academic Skills Workshop**

*Grant Writing*

SUNDAY, NOVEMBER 10 | 7-8am

Program Chairs: David E. Kaplan and Wendy A. Henderson

1.0 CME Credits

Demystify grant applications at this workshop designed for early-career investigators. Instructors will walk through major components of a scientific grant application and provide insight into the submission and peer review processes. They will outline strategies to address different sections of the typical federal or foundation scientific grant proposal process.

**Basic Research Workshop**

*A New Era of Genomics and Biomarkers in Hepatocellular Carcinoma*

SUNDAY, NOVEMBER 10 | 8 am-Noon

Program Chairs: Tushar Patel and Emmanuel Thomas

3.75 CME Credits

Recent research and emerging technologies have revealed new signaling pathways and genes involved in hepatocellular cancer development, as well as biomarkers to aid surveillance and early detection of HCC. Eight investigators will discuss emerging basic research and their translational application to enhance early diagnosis of HCC and advance the effort to limit morbidity and mortality in this patient population.

**Hepatology Associates Course**

SUNDAY, NOVEMBER 10 | 8 am-Noon

Program Chairs: Amanda J. Chaney and Jeffrey P. McMahon

3.75 CME Credits  3.75 CE Credits

*Eligible for 1.75 Pharmacology Credits*

This comprehensive program will offer the hepatology provider updated information on managing patients with liver disease and/or in the post-transplant setting. Speakers will review new evidence and the latest tools to help providers deliver high-quality patient care, change practice approaches where needed and help improve patient outcomes.

**Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture**

*Clinical vs. Science in Personalizing Immunosuppression*

SUNDAY, NOVEMBER 10 | 9:30-10 am

Presenter: Abraham Shaked

Moderator: David C. Mulligan

0.5 CME Credits  0.5 ABIM MOC Points

Immunosuppression in the liver transplant setting includes multiple drugs aimed at predetermined trough levels, adjusted to time after transplantation. Excellent graft and patient survival supports immunosuppression, but there may be significant short- and long-term risks. At this presentation, experts will discuss clinical approaches to immunosuppression in liver transplant patients, including biomarkers used for safe personalization of this process.
General Hepatology Update
SUNDAY, NOVEMBER 10 | 10:30 am-Noon
Program Chairs: Virginia Clark and Ayako Suzuki
1.5 CME Credits 1.5 ABIM MOC Points

If you are a general practitioner caring for patients with a variety of liver diseases, this hepatology update is designed for your needs. Review significant new findings in hepatology and how they may affect current clinical practice, ask questions and discuss challenges faced in daily clinical settings.

Alcoholic Liver Disease SIG
Emerging Therapies and Current Clinical Trials for Alcoholic Hepatitis
SUNDAY, NOVEMBER 10 | 10:30 am-12:30 pm
Program Chairs: Crag J. McClain and Ashwani K. Singal
2.0 CME Credits

Review data from ongoing clinical trials for alcoholic hepatitis, explore the role of early liver transplantation and discuss the management of alcohol use disorder in patients with alcoholic hepatitis and acute on chronic liver failure. Topics covered include trial design considering standards of care and liver transplantation’s emerging role and subject recruitment challenges for clinical trials in alcoholic hepatitis.

Diversity Workshop
Social Innovation: Solution-Based Responses to Disparities in Liver Diseases and Liver Transplantation
SUNDAY, NOVEMBER 10 | 10:30 am-12:30 pm
Program Chairs: Carla W. Brady and Mauricio Lisker-Melman
2.0 CME Credits

The Diversity and Inclusion Committee promotes health disparities research and efforts to improve health outcomes among ethnic and racial groups who carry a higher burden of liver disease. Based on positive feedback from the 2018 workshop on Ethnic and Racial Disparities in Liver Disease, this two-hour workshop reviews current programmatic efforts to eliminate disparate outcomes in liver disease and liver transplantation.

Hepatobiliary Neoplasia SIG
Obesity, Metabolic Syndrome and HCC
SUNDAY, NOVEMBER 10 | 2-4 pm
Program Chairs: Josep M. Llovet and Jessica Zucman-Rossi
2.0 CME Credits

Experts share new research in molecular hepatocarcinogenesis in the setting of NASH at this program, including global obesity trends, the association of metabolic syndrome and HCC, and HCC surveillance in patients with NASH/metabolic syndrome. They will present and compare evidence on HCC diagnosis and management specific to patients with obesity that may be applied to clinical practice.

Hepatology Associates SIG
Multi-Disciplinary Approach in Reducing Readmissions
SUNDAY, NOVEMBER 10 | 2-4 pm
Program Chairs: Vicki Shah and Barbara G. Andrews 2.0 CME Credits

Patient and caregiver education, and transition to care are important aspects for hospital discharge. At this informative program, experts will review multidisciplinary strategies to optimize discharge planning and share innovative models of outpatient care in liver disease, including empowering patients and caregivers, decreasing risk factors and the incidence of hospital readmissions, and reducing costs.
Maintenance of Certification (MOC) Update

Where Are We Now?

SUNDAY, NOVEMBER 10 | 2-4 pm
Program Chairs: Heather M. Patton, Helen S. Te and Mark W. Russo
2.0 CME Credits 2.0 ABIM MOC Points

Discuss the current state of the ABIM Maintenance of Certification (MOC) program for gastroenterologists and transplant hepatologists at this update. Speakers will review the expense, time commitment and relevance of this program’s requirements; current MOC requirements in the program; the means to meet these requirements; progress made in addressing concerns from ABIM diplomats; and alternative pathways to board recertification.

Value-Based Medicine in Hepatology

Defining the Role of Hepatologists in Value-Based Care

SUNDAY, NOVEMBER 10 | 2-4 pm
Program Chairs: Meena B. Bansal and Ziad F. Gellad
2.0 CME Credits 2.0 ABIM MOC Points

Value-based arrangements are increasingly becoming part of the healthcare landscape. The goal of this program is to educate and empower hepatologists to be valuable contributors to the success of these new arrangements and play an active role in developing and implementing beneficial approaches.

President’s Choice Lecture

SUNDAY, NOVEMBER 10 | 4-4:30 pm
Presenter: Tachi Yamada
Moderator: Michael W. Fried
0.5 CME Credits 0.5 ABIM MOC Points

In the world’s poorest nations, the appalling loss of life from easily treated or preventable illnesses represents a moral tragedy. This year’s President’s Choice Lecture explores potential strategies to correct this inequity, including collaborative partnerships among medical professionals, ways to accurately measure the impact of global disease management efforts and the innovative solutions necessary to accomplish this great task.

Transplant Hepatology Fellowship Program Director’s Workshop

Defining the Hepatology Workforce Study in the U.S.

SUNDAY, NOVEMBER 10 | 4-6 pm
Program Chairs: Ian R. Schreibman and Omar Y. Mousa
2.0 CME Credits

This interactive workshop will focus on ACGME core requirement updates and the 2.0 milestones. Presenters will provide new insights on the transplant hepatology workforce, including current demographics and future demand in the field. They will present the top two research projects on transplant hepatology education and training and lead an open discussion forum with the audience to address unmet needs.
AASLD/APASL Joint Symposium

Acute on Chronic Liver Failure

SUNDAY, NOVEMBER 10 | 4:15-6:15 pm
Program Chairs: Diana A. Payawal and Hugo E. Vargas
2.0 CME Credits

Acute on Chronic Liver Failure (ACLF) is a well-recognized rapid course of liver disease that can have devastating consequences on patients. At this symposium, faculty will discuss ACLF’s common triggers and explore current perspectives of management in the context of these triggering events. Topics covered include microbiome analysis to identify high-risk patients and the role of transplantation.

Monday, November 11

Academic Skills Workshop

Journal Editors Session: How to Get Published in an AASLD Journal 2.0

MONDAY, NOVEMBER 11 | 7-8am
Program Chairs: David E. Cohen, Paul Martin, Nancy Reau and Gyongyi Szabo
1.0 CME Credits

Explore strategies to increase the chances of manuscript acceptance in one of AASLD’s four journals. At this workshop, four Editors-in-Chief will provide tips, feedback and guidance in small breakout groups, answering your questions on Open Access, author guidelines and cascading manuscripts from other AASLD journals. First-time authors and early career researchers will benefit from insights relevant to each individual journal.

Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture

Genetic Susceptibility to Drug-Induced Liver Injury

MONDAY, NOVEMBER 11 | 10-10:30 am
Presenter: Ann K. Daly
Moderator: Victor J. Navarro
0.5 CME Credits 0.5 ABIM MOC Points

Key risk factors for development of drug-induced liver injury (DILI), especially genetic factors like HLA associations, are the focus of this lecture. Speakers will explore other genetic risk factors that may contribute to DILI and discuss recent data showing how the non-HLA gene PTPN22 may contribute to DILI due to the use of a number of different drugs.

Advances for Practitioners

New AASLD Guidelines: Updated Recommendations and Ongoing Challenges in HCC, PBC and ALD

MONDAY, NOVEMBER 11 | 10:30 am-12:30 pm
Program Chairs: George Ioannou and Amit G. Singal
2.0 CME Credits 2.0 ABIM MOC Points

AASLD Guideline/Guidance Statements on treating hepatocellular carcinoma (HCC), primary biliary cholangitis (PBC) and alcohol-related liver disease (ALD) are now updated to reflect data published since 2010, when the previous versions were released. At this session, the guidelines’ authors will highlight important changes hepatologists should know and discuss controversial or challenging issues in treating patients with these chronic liver diseases.
Hans Popper Basic Science State-of-the-Art Lecture

*Distributed Hepatocytes in Liver Homeostasis and Regeneration*

**MONTDAY, NOVEMBER 11 | 2-2:30 pm**

Presenter: Steven Artandi
Moderator: Adrian M. Di Bisceglie

0.5 CME Credits  0.5 ABIM MOC Points

The annual Hans Popper Lecture clarifies exciting new findings on cellular renewal mechanisms in liver disease and liver cancer. A subset of hepatocytes with high levels of telomerase are distributed throughout the liver lobule, serving to renew the organ during homeostasis and in response to injury. Learn how genetic ablation of these hepatocytes results in scarring and defective regenerative responses.

Emerging Trends Symposium

*Microelimination of Viral Hepatitis–Positive Use in Organ Transplantation*

**MONTDAY, NOVEMBER 11 | 2-4 pm**

Program Chairs: Jordan J. Feld and Gregory Dore

2.0 CME Credits

HCV-infected organs are now being used for transplantation to HCV-uninfected recipients. This program will review existing data on both liver and non-liver transplantation from HCV-positive donors to HCV-negative recipients and key ethical and practical issues related to HCV-infected donor organs, including whether this should be done only in clinical trials or could be accepted as standard of care.

Global Forum

*Alcohol-Related Liver Disease: Seeking Local Solutions to a Global Problem*

**MONTDAY, NOVEMBER 11 | 2-4 pm**

Program Chairs: Michael R. Lucey and K. Rajender Reddy

2.0 CME Credits

Harmful alcohol use accounts for three million annual global deaths. Experts discuss the global health burden of alcohol-related liver disease (ALD), reporting on ALD’s impact in Africa, Latin America and Asia, region-specific factors that promote or hinder solutions and how forthcoming AASLD guidance on ALD may serve as a template to implement effective prevention and treatment strategies worldwide.

Liver Transplantation and Surgery SIG and Pediatric Liver Disorders SIG

*Optimizing Allograft Health Over a Lifetime*

**MONTDAY, NOVEMBER 11 | 2-6 PM**

Program Chairs: Veena L. Venkat and Timucin Taner

4.0 CME Credits

Discover how allocation impacts long-term outcomes for the transplant recipient and liver graft at this session. Speakers will address ways to improve the ability to interpret and identify the significance of long-term, post-transplant liver biopsy findings and offer tools to expand one's perspective on individualizing immunosuppression to optimize long-term outcomes for the allograft and recipient.
**Basic Debrief**  
MONDAY, NOVEMBER 11 | 4-4:30 pm  
Presenter: Gavin E. Arteel  
Moderator: Harmeet Malhi  
No CME Offered  

Don’t overlook any of the groundbreaking basic science research presented at The Liver Meeting®. New this year, an expert will briefly review all the basic science abstracts presented at the meeting in one condensed session.

**Women’s Health Program**  
*Pregnancy in Liver Disease*  
MONDAY, NOVEMBER 11 | 4-6 pm  
Program Chairs: Monika Sarkar and Kidist K. Yimam  
CME Credits: 2.0  
ABIM MOC Points: 2.0  

How can women with liver diseases or organ transplants have healthier pregnancies? Careful, multidisciplinary management is key. This session will provide key updates in this area, covering topics like contraception use and pregnancy management across a spectrum of liver diseases, including the liver trans-plant population.

**Leon Schiff State-of-the-Art Lecture**  
*Molecular Pathogenesis and Management of Hepatocellular Carcinoma*  
TUESDAY, NOVEMBER 12 | 9:30-10 am  
Presenter: Josep M. Llovet  
Moderator: David E. Kaplan  
CME Credits: 0.5  
ABIM MOC Points: 0.5  

At the 2019 Leon Schiff State-of-the-Art Lecture, our selected speaker will provide a thorough overview of the advances in knowledge of the pathogenesis of hepatocellular carcinoma (HCC). The lecture will explore current data on evidence-based treatment of this disease, including novel molecular therapies and advances in precision oncology.

**Hepatitis Debrief**  
TUESDAY, NOVEMBER 12 | 11:30 am-Noon  
Presenter: Marc G. Ghany  
Moderator: Raymond T. Chung  
No CME Offered  

Digest a debrief of the newest data on the treatment of viral hepatitis presented at The Liver Meeting® in 2019. This unique session synthesizes the results from this year’s abstracts, condensed and discussed by an expert in the field.

**NAFLD Debrief**  
TUESDAY, NOVEMBER 12 | Noon-12:30 pm  
Presenter: Kathleen E. Corey  
Moderator: Raymond T. Chung  
No CME Offered  

Review key highlights from all the exciting clinical research presented at The Liver Meeting® this year at this condensed round-up session, which is designed to complement the highly regarded Hepatitis and Clinical Hepatology Debriefs.

**Clinical Hepatology Debrief**  
TUESDAY, NOVEMBER 12 | 12:30-1 PM  
Presenter: Michael R. Charlton  
Moderator: Raymond T. Chung  
No CME Offered  

Review a condensed summary of the clinical research highlights from The Liver Meeting® in 2019. This popular debriefing session summarizes all the important findings in clinical hepatology that were presented this year.
Exhibit Hall

SATURDAY, NOVEMBER 9-MONDAY, NOVEMBER 11

With more than 90 companies present in the exhibit hall, you will have access to the latest products, services and technology related to hepatology. From the opening reception to daily coffee breaks, this important component of The Liver Meeting® 2019 extends networking beyond the sessions. For the full list of exhibitors, visit aasld.org/livermeeting and click on the "Exhibit & Support Info" tab.

<table>
<thead>
<tr>
<th>Halls C &amp; D</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, November 9</td>
<td>5-7:30 pm</td>
</tr>
<tr>
<td>Sunday, November 10</td>
<td>9:30 am-3 pm</td>
</tr>
<tr>
<td>Monday, November 11</td>
<td>9:30 am-3 pm</td>
</tr>
</tbody>
</table>

Poster Sessions

Approximately 2,000 basic science and clinical posters will be scheduled for presentation, providing an opportunity for authors to both display and discuss their research. If you have a particular research interest, be sure to meet the authors during their available times below and ask them about their project.

<table>
<thead>
<tr>
<th>Friday, November 8</th>
<th>8 am-5:30 pm</th>
<th>Presenters Available: 12:30-1:30 pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, November 9</td>
<td>2-7 pm</td>
<td>Presenters Available: 5:15-6:15 pm</td>
</tr>
<tr>
<td>Sunday, November 10</td>
<td>8 am-5:30 pm</td>
<td>Presenters Available: 12:30-1:30 pm</td>
</tr>
<tr>
<td>Monday, November 11</td>
<td>8 am-5:30 pm</td>
<td>Presenters Available: 12:30-1:30 pm</td>
</tr>
</tbody>
</table>

Attendees can view ePosters at stations located in the John B. Hynes Memorial Convention Center. Browse abstracts by day, topic, author, and keywords, as well as leave comments and questions for the presenting author. In addition, ePosters will be available on LiverLearning® after the meeting.

Plenary Sessions

Plenary sessions feature didactic presentations representing the most outstanding scientific research submitted to AASLD. Presenters will have 10 minutes to discuss their research, followed by a five-minute Q&A period. Three Presidential Plenary sessions and two Liver Transplant Plenary sessions each will offer six distinguished abstract presentations.

<table>
<thead>
<tr>
<th>Sunday, November 10</th>
<th>8-9:30 am</th>
<th>Liver Transplant Plenary I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, November 10</td>
<td>10:30 am-Noon</td>
<td>Liver Transplant Plenary II</td>
</tr>
<tr>
<td>Monday, November 11</td>
<td>8-9:30 am</td>
<td>Presidential Plenary (Clinical)</td>
</tr>
<tr>
<td>Monday, November 11</td>
<td>11 am-12:30 pm</td>
<td>Presidential Plenary (Basic)</td>
</tr>
<tr>
<td>Tuesday, November 12</td>
<td>9-10:30 am</td>
<td>Presidential Plenary (Translational)</td>
</tr>
</tbody>
</table>
Parallel Sessions

SUNDAY, NOVEMBER 10–MONDAY, NOVEMBER 11

Similar to plenary sessions, parallel sessions feature 10-minute research presentations followed by a five-minute Q&A period. Parallel sessions run concurrently and are organized by specialized scientific topic. Feel free to stay for an entire parallel session, or attend multiple sessions that are of interest to you.

Parallel sessions feature the following topics:

- Acute Liver Failure
- Alcoholic Liver Disease
- Cell and Molecular Biology
- Cirrhosis
- Fibrosis Research
- Genomics and Precision Medicine
- Gut Liver Axis and Microbiome
- Health Services Research
- Hepatitis B
- Hepatitis C
- Hepatobiliary Neoplasia
- Hepatocellular Carcinoma and Cholangiocarcinoma
- Hepatotoxicity
- Liver Transplantation
- Nonalcoholic Fatty Liver Disease
- PBC/PSC and Other Cholestatic Diseases
- Pediatric and Metabolic Liver Disease
- Portal Hypertension
- Steatohepatitis and Nonalcoholic Steatohepatitis

Late-Breaking Abstracts

These late-breaking abstract sessions aim to present the most current research in the field, featuring large clinical studies or high-impact translational research that has been completed recently before the meeting.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, November 11</td>
<td>2:30-4 pm</td>
<td>Late-breaking Oral Abstract Session I</td>
</tr>
<tr>
<td>Tuesday, November 12</td>
<td>8-9 am</td>
<td>Late-breaking Oral Abstract Session II</td>
</tr>
</tbody>
</table>
**TICKETED SESSIONS**

See p. 32 for pricing

### AASLD/ILTS Transplant Course

**The Critically Ill Patient and Challenges in Liver Transplantation**

FRIDAY, NOVEMBER 8 | 8 am-3:30 pm

Program Chairs: Sanjiv Saigal, MD; Catherine Paugam-Burtz, MD, PhD and Roberto Hernandez-Alejandro, MD

6.25 CME Credits  6.0 CE Credits

This course will review the perioperative challenges faced in very sick liver transplant candidates, and is useful for intensivists, hepatologists, anesthesiologists and surgeons. Liver transplantation outcomes in sick patients significantly depend on perioperative management. Faculty will address the special challenges faced in liver transplantation, including those of living donor organs.

See p. 32 for pricing

### AASLD/ASGE Endoscopy Course

**New Endoscopic Frontiers in Liver Disease**

FRIDAY, NOVEMBER 8 | 8 am-4 pm

Program Chairs: Sung Uk Jang, MD and Reem Sharaiha, MD, MSc

6.25 CME Credits

Appropriate, adequate management of patients during endoscopy is vital. At this informative session, speakers will review standards of care for sedation and managing coagulopathy and how to manage upper GI bleeds, including variceal and non-variceal. They will address the latest advances in managing biliary complications of liver transplant and review hepatobili-ary endoscopic ultrasounds and endoscopic treatment of fatty liver.
Meet-the-Professor Luncheons

These highly interactive, small group sessions are opportunities for attendees to engage with well-known liver disease experts. Both researchers and clinicians can ask questions, explore a wide variety of timely topics and network with both peers and leaders in the field.

<table>
<thead>
<tr>
<th>CLINICAL LUNCHEONS</th>
<th>Saturday, November 9</th>
<th>Noon-1:30 pm</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MTP 01</strong></td>
<td><strong>Ask the Expert on Cirrhosis: What are the Best Strategies to Avoid Readmissions?</strong></td>
<td>Mark Russell and Fasiha Kanwal</td>
</tr>
<tr>
<td><strong>MTP 02</strong></td>
<td><strong>Ask the Expert on Portal Hypertension: Are there Useful Clinical and Laboratory Predictors to Identify and Treat Portal Hypertension?</strong></td>
<td>Guadalupe Garcia-Tsao and Juan Abraldes</td>
</tr>
<tr>
<td><strong>MTP 03</strong></td>
<td><strong>Ask the Expert on Hepatitis B: What is the Best Strategy to Treat Patients Who Relapse After Reduction of Immunosuppression?</strong></td>
<td>Gideon Hirschfield and Michael Heneghan</td>
</tr>
<tr>
<td><strong>MTP 04</strong></td>
<td><strong>Clinical Studies in NAFLD: Where are We Now?</strong></td>
<td>Stephen Harrison and Michael R. Charlton</td>
</tr>
<tr>
<td><strong>MTP 05</strong></td>
<td><strong>Challenges in Pediatric NASH</strong></td>
<td>Marialena Mouzaki and Rohit Kohli</td>
</tr>
<tr>
<td><strong>MTP 06</strong></td>
<td><strong>Emerging Treatments in Alcoholic Liver Disease</strong></td>
<td>Vijay Shah and Ashwani Singal</td>
</tr>
<tr>
<td><strong>MTP 07</strong></td>
<td><strong>Management of the Critically Ill Cirrhotic Patient</strong></td>
<td>Jody Olson and Oren K. Fix</td>
</tr>
<tr>
<td><strong>MTP 08</strong></td>
<td><strong>Using Hepatitis C Positive and PHS Increased Risk Organs: Practice and Pitfalls</strong></td>
<td>Michael Curry and Surakit Pungpapong</td>
</tr>
<tr>
<td><strong>MTP 09</strong></td>
<td><strong>Immunosuppression Withdrawal in the Transplant Child: Where Do We Stand?</strong></td>
<td>Sandy Feng and John Bucuvalas</td>
</tr>
<tr>
<td><strong>MTP 10</strong></td>
<td><strong>Personalizing Immunosuppression in the Adult Liver Transplant Recipient</strong></td>
<td>Josh Levitsky and Sumeet Asrani</td>
</tr>
<tr>
<td><strong>MTP 11</strong></td>
<td><strong>Interpreting Genetic Testing in Cholestasis: Kids and Adults</strong></td>
<td>Sylvia Vilarinho and Richard Thompson</td>
</tr>
<tr>
<td><strong>MTP 12</strong></td>
<td><strong>When to Pursue Bariatric Surgery in Patients with Advanced NASH?</strong></td>
<td>Julie Heimbach and Naga Chalasani</td>
</tr>
<tr>
<td><strong>MTP 13</strong></td>
<td><strong>Screening for Hepatic Encephalopathy—Does My Patient Have Minimal Encephalopathy?</strong></td>
<td>Jasmohan Bajaj and Rajiv Jalan</td>
</tr>
</tbody>
</table>
# Meet-the-Professor Luncheons (continued)

<table>
<thead>
<tr>
<th>BASIC LUNCHEONS</th>
<th>Saturday, November 9</th>
<th>11:45 am-1:15 pm</th>
</tr>
</thead>
</table>
| MTP 16           | Liver Regeneration and Hepatocellular Carcinoma  
Wendong Huang and Sayeepriyadarshini Anakk |
| MTP 17           | Inflammation, Fibrosis and Liver Repair  
Bin Gao and Frank Tacke |
| MTP 18           | Progressive Injury in NAFLD  
Ariel Feldstein and Hugo Rosen |
| MTP 19           | Epigenetic Regulation of Alcohol-Induced Liver Injury and Repair  
X. Charlie Dong and Chiung-Kuei Huang |
| MTP 20           | Autophagy Related Liver Injury and Repair  
Bilon Khambu and Xiao-Ming Yin |
Early Morning Workshops

Kick-start your day at The Liver Meeting® with these highly interactive sessions focusing on specialized areas of liver disease or investigation. Early birds will enjoy both the stimulating discussions of new science and the opportunity to network with experts and peers in a small group setting.

### BASIC WORKSHOPS

<table>
<thead>
<tr>
<th>Workshop Code</th>
<th>Title</th>
<th>Facilitators</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMW 01</td>
<td>Molecular Pathogenesis of Intrahepatic Cholangiocarcinoma</td>
<td>Gregory Gores and Alphonse Sirica</td>
</tr>
<tr>
<td>EMW 02</td>
<td>FGF-15 and FXR: Signals for Liver Regeneration</td>
<td>Grace Guo and Matias A. Avila</td>
</tr>
<tr>
<td>EMW 03</td>
<td>Inflammasome and the Liver-Gut Axis</td>
<td>Wajahat Mehal and Hartmut Jaeschke</td>
</tr>
<tr>
<td>EMW 04</td>
<td>Sinusoidal Cells in Chronic Liver Disease: Microcirculatory Dysfunction and Portal Hypertension</td>
<td>Yasuko Iwakiri and Jordi Gracia-Sancho</td>
</tr>
<tr>
<td>EMW 05</td>
<td>Microbiome and Mycobiome in Alcoholic Liver Disease</td>
<td>Gyongyi Szabo and Jasmohan Bajaj</td>
</tr>
<tr>
<td>EMW 06</td>
<td>Generating Hepatocytes from iPSC: Promise and Perils</td>
<td>Stephen A. Duncan and Akihiro Asaij</td>
</tr>
</tbody>
</table>

### CLINICAL WORKSHOPS

<table>
<thead>
<tr>
<th>Workshop Code</th>
<th>Title</th>
<th>Facilitators</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMW 07</td>
<td>Palliative Care for the ACLF Patient in the ICU: The Views of the Hepatologist and an Intensivist</td>
<td>Constantine Karvellas and Puneeta Tandon</td>
</tr>
<tr>
<td>EMW 08</td>
<td>Mother to Child Transmission of Viral Hepatitis B and C</td>
<td>Nancy Reau and Maureen Jonas</td>
</tr>
<tr>
<td>EMW 09</td>
<td>Genetic Predisposition to Hepatotoxicity</td>
<td>Andrew Stolz and Paul Watkins</td>
</tr>
<tr>
<td>EMW 10</td>
<td>Immune Dysregulation in Pediatric Acute Liver Failure</td>
<td>Estella Alonso and John Bucuvalas</td>
</tr>
<tr>
<td>EMW 11</td>
<td>Non-Cirrhotic Portal Hypertension: Is There Clarity in Diagnosis?</td>
<td>Theo Heller and Pierre-Emmanuel Rautou</td>
</tr>
<tr>
<td>EMW 12</td>
<td>HCV Reinfection: Who, When and How to Treat?</td>
<td>Daniel Fierer and Gregory Dore</td>
</tr>
<tr>
<td>EMW 13</td>
<td>Treatment-Refractory Autoimmune Hepatitis in Children and Adults</td>
<td>Nanda Kerkar and David Assis</td>
</tr>
<tr>
<td>EMW 14</td>
<td>Liver Biopsy in Diagnosis and Management of Pediatric and Adult NASH</td>
<td>Marialena Mouzaki and Naga Chalasani</td>
</tr>
<tr>
<td>EMW 15</td>
<td>Career Development for Health Services Research in Hepatology</td>
<td>Fasiha Kanwal and Lisa VanWagner</td>
</tr>
</tbody>
</table>

Space is limited. REGISTER EARLY!
### BASIC WORKSHOPS

| EMW 16 | Novel Approaches to Study and Treat Liver Fibrosis |
| EMW 17 | Models Systems to Study Cholestasis: Mice, Zebrafish and Organoids |
| EMW 18 | New HBV Assays: What Do They Mean and How Should They be Used? |
| EMW 19 | The Impact of Thermoneutral Environment in Mouse Models of NAFLD/NASH |
| EMW 20 | Immune Checkpoints in Mechanisms of HCC |
| EMW 21 | Wnt Signaling in Liver Development and Carcinogenesis |
| EMW 22 | Lipid Droplet Biology in Alcoholic / Nonalcoholic Liver Disease |

### CLINICAL WORKSHOPS

| EMW 23 | Combination Therapies for Advanced HCC |
| EMW 24 | End-Points for Treatment of PSC |
| EMW 25 | Improving Access to Care: The Evolving Role of Telemedicine |
| EMW 26 | Clinical Trials in PBC |
| EMW 27 | Biliary Atresia: Defining End-Points for Clinical Trials |
| EMW 28 | Transplantation of HCV-Infected Donor Organs into Uninfected Recipient |
| EMW 29 | Taking the Patient with Cirrhosis to Surgery: An Evidence-Based Risk Assessment |
| EMW 30 | Recurrence of Autoimmune Hepatitis after Liver Transplantation |
### BASIC WORKSHOPS

**Monday, November 11 | 6:45-7:45 am**

| EMW 31 | Platelets in Cirrhosis: Role in Fibrogenesis and Coagulation | Yury Popov and Jasimuddin Ahamed |
| EMW 32 | New Receptors in Liver Disease | Natalie Torok and Francisco Javier Cubero |
| EMW 33 | RAGE and New Mechanisms of Fibrosis | Natalia Nieto and Mario Strazzabosco |
| EMW 34 | Novel Mechanisms of Experimental NASH | Anne S. Henkel and Anna Mae Diehl |
| EMW 35 | Engineering of Biliary Organoids | Robert Huebert and Carol Soroka |
| EMW 36 | Extracellular Vesicles in Liver Pathobiology | Ariel Feldstein and Harmeet Malhi |

### CLINICAL WORKSHOPS

**Monday, November 11 | 6:45-7:45 am**

| EMW 37 | Acute on Chronic Liver Failure: Treating Infections in the Era of MDR Pathogens | Salvatore Piano and Jasmohan Bajaj |
| EMW 38 | Frailty and Sarcopenia in Cirrhosis: Measurement and Action | Michael Dunn and Aldo J. Montano-Loza |
| EMW 39 | Abstract and Poster Presentation Best Practices | Russell Fleischer and Jacqueline O'Leary |
| EMW 40 | New Drugs and End-Points for NASH | Rohit Loomba and Alina Allen |
| EMW 41 | Managing Pregnancy in Chronic Liver Disease | Tatyana Kushner and Vandana Khungar |
| EMW 42 | Liver Transplantation for Alcoholic Hepatitis | Gene Im and Michael Lucey |
| EMW 43 | Quality and Safety for Hospitalized Patients with Cirrhosis | Fasiha Kanwal and Elliot Tapper |
| EMW 44 | Emerging Antifibrotic Therapy | Manal Abdelmalek and Meena Bansal |
| EMW 45 | Fontan Hepatopathy: Monitoring Progression of Liver Disease | Douglas A. Simonetto and Daniel Ganger |